Health Condition 1: null- Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Alone.
Conditions
Interventions
Intervention1: Fixed Dose Combination of Teneligliptin 20 mg and Metformin 1000 mg Tablets: administered 1 or 2 tablet/s once daily for 24 weeks
Control Intervention1: Metformin 1000 mg Tablets: admin
Sponsors
Glenmark Pharmaceuticals Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients age >=18 and 2. Patients with Type 2 Diabetes Mellitus who have been treated with upto 1 gram per day of Metformin monotherapy for at least 3 months prior to screening and having inadequate glycaemic control [Glycosylated Haemoglobin (HbA1c) levels of >7% to
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women. 2. Female Patient of child bearing potential who do not agree to remain abstinent or use medically acceptable methods of contraception during the study therapy and for 4 weeks after the end of study therapy. 3. Patient with Type 1 diabetes mellitus or secondary form of diabetes. 4. Patients with known hypersensitivity to any of the components of the formulation. 5. Known cases of diabetic nephropathy, diabetic ketoacidosis, diabetic coma, hyperglycemia hyperosmolar state, retinopathy, neuropathy or other diabetic complications of sufficient severity to require treatment like severe Peripheral Neuropathy, Symptomatic Orthostatic Hypotension, Urinary Retention, Foot ulcers, or Gastric Stasis. 6. Patients who have a recent history or who are currently known to abuse alcohol or drugs. 7. Patients with clinically significant renal, hepatic, or cerebrovascular disease, known pituitary or gastric dysfunction, malignancy, thyroid dysfunction, chronic uncontrolled systemic diseases like asthma, collagen disorders, severe infection etc. or any other medical illness that may affect patient safety or difficult to evaluate the efficacy of the product. 8. Patients receiving treatment with systemic corticosteroids. 9. Patients who have participated in any clinical trial in the past 1 month. 10. Any other condition that in the opinion of the Investigator that does not justify the patientâ??s participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean Change in Glycosylated Haemoglobin (HbA1c) levelsTimepoint: 24 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Mean Change in Fasting and Postprandial Plasma Glucose (FPG and PPG)Timepoint: 24 weeks;Proportion of patients achieving the goal of HbA1c â?¤7% levelTimepoint: 24 weeks | — |
Countries
India
Contacts
Public ContactAmol Pendse
Glenmark Pharmaceuticals Ltd
Outcome results
None listed